Organism: Homo sapiens
Gene: 1553634_a_at
Selected probe(set): 1553634_a_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553634_a_at (1553634_a_at) across 6673 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):-1.8646984
Number of Samples:20 / 19

Experimental	atopic dermatitis study 12 (non-lesional; adults)
	Unaffected skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis.
Control	atopic dermatitis study 12 (non-lesional; children)
	Unaffected buttock skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All patients had moderate-to-severe disease (SCORAD score: mean, 57.8; range, 33-84) with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded.

Relative Expression (log2-ratio):1.8260956
Number of Samples:4 / 4

Experimental	BEZ235 study 1 (3.606 uM)
	A2058 cells treated with 3.606 uM NVP-BEZ235 for 24hours. The concentration corresponding to the IC90 of BKM120. Cells were maintained in DMEM, high glucose, 10% FCS, 1% pyruvate, 2% glutamine. BEZ235 is a mTOR/PI3K inhibitor; alternative names: [NVP-BEZ235] ATC code:---
Control	vehicle (DMSO) treated A2058 cell samples
	A2058 cells treated with vehicle (0.1% DMSO) for 24hours. Cells were maintained in DMEM, high glucose, 10% FCS, 1% pyruvate, 2% glutamine.

Relative Expression (log2-ratio):-1.7796631
Number of Samples:2 / 29

Experimental	juvenile psoriatic arthritis study 1
	Peripheral blood mononuclear cell (PBMC) samples from children with juvenile psoriatic arthritis. All patients were free of disease modifying antirheumatic drugs.
Control	normal PBMC sample
	Peripheral blood mononuclear cell (PBMC) samples from healthy children; age (mean ± SD): 10.8 ± 5.3 years.

Relative Expression (log2-ratio):1.686985
Number of Samples:8 / 25

Experimental	psoriasis study 11 (lesional; brodalumab; 15d; 700mg)
	Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 15 (week 2) after treatment with a single dose (700 mg i.v.) of brodalumab. ATC code:
Control	psoriasis study 11 (lesional; baseline)
	Lesional skin punch biopsy samples derived from patients with moderate to severe plaque psoriasis before treatment.

Relative Expression (log2-ratio):-1.6836033
Number of Samples:20 / 18

Experimental	atopic dermatitis study 12 (lesional; adults)
	Lesional skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis.
Control	atopic dermatitis study 12 (lesional; children)
	Lesional popliteal skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All biopsy specimens were from chronic lesions present for more than 72 hours. All patients had moderate-to-severe disease with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded.

Relative Expression (log2-ratio):-1.6712351
Number of Samples:20 / 11

Experimental	atopic dermatitis study 12 (lesional; adults)
	Lesional skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis.
Control	normal skin tissue (adults)
	Skin biopsy samples from healthy adults (age range 38–57 years).

Relative Expression (log2-ratio):1.5739107
Number of Samples:8 / 5

Experimental	psoriasis study 11 (lesional; brodalumab; 15d; 700mg)
	Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 15 (week 2) after treatment with a single dose (700 mg i.v.) of brodalumab. ATC code:
Control	psoriasis study 11 (lesional; placebo; 15d)
	Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 15 (week 2) after treatment with placebo.

Relative Expression (log2-ratio):1.5306454
Number of Samples:3 / 3

Experimental	peptidoglycan study 1
	Healthy neonatal neutrophils with ≥ 99% purity isolated from cord blood samples collected after normal, full-term, vaginal delivery treated with peptidoglycan isolated from S. aureus (10 ug/ml) for 4 hours.
Control	mock treated neonatal neutrophils
	Healthy neonatal neutrophils with ≥ 99% purity isolated from cord blood samples collected after normal, full-term, vaginal delivery mock treated for 4 hours.

Relative Expression (log2-ratio):1.5236158
Number of Samples:4 / 4

Experimental	BEZ235 study 1 (IC90)
	A2058 cells treated with NVP-BEZ235 for 24hours at an IC90 concentration. Concentration of IC90 was judged by reduction of pAkt levels (S473P-Akt inhibition) and the value is not clear from the article. Cells were maintained in DMEM, high glucose, 10% FCS, 1% pyruvate, 2% glutamine. BEZ235 is a mTOR/PI3K inhibitor; alternative names: [NVP-BEZ235] ATC code:---
Control	vehicle (DMSO) treated A2058 cell samples
	A2058 cells treated with vehicle (0.1% DMSO) for 24hours. Cells were maintained in DMEM, high glucose, 10% FCS, 1% pyruvate, 2% glutamine.

Relative Expression (log2-ratio):1.5113859
Number of Samples:8 / 2

Experimental	glioma study 16 (astrocytoma)
	Primary astrocytoma tissues obtained from the operating room. Tumors were diagnosed and graded according to the current WHO classification (grade III-IV).
Control	normal brain tissue
	Normal brain tissue sample from healthy donors.